Component
Intravenous immunoglobulin
Intravenous immunoglobulin. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
In two single-patient studies, one in a patient with metastatic colorectal cancer who received BTH1677 combined with the tumour targeting antibody cetuximab and a second in a patient with metastatic neuroendocrine tumour who received BTH1677 combined with the immune checkpoint inhibitor pembrolizumab, the patients had low serum titres of antibodies against beta-glucan and low innate immune effector functionality induced by BTH1677, and addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoural activity with long-term disease control.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- evidence_span
- {"source_cache": "artifacts/glucan-research/32132045.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7dea757c889af10839a38a317d704760e7e15798bc15a5da3a1323ec4143cf42", "start_char": 0, "end_char": 1102, "text_sha256": "7dea757c889af10839a38a317d704760e7e15798bc15a5da3a1323ec4143cf42"}
- experimental_model
- Two single-patient reports of immunoglobulin infusion in patients with low anti-glucan antibody
- exposure
- BTH1677 with cetuximab or with pembrolizumab, plus intravenous immunoglobulin
- limitations
- Two patients. This is an anecdotal test of a mechanism, not evidence of treatment benefit, and no control condition exists for the tumour outcome.
- nutrient_topic
- Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
- organism
- Human
- plain_language
- Two patients who lacked the antibody were given antibody, and the drug started working.
- primary_references
- [bg-p32132045] Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan. (2020). https://pubmed.ncbi.nlm.nih.gov/32132045/ DOI: 10.21873/anticanres.14090
- tissue_or_cell_type
- Peripheral blood and tumour
- trigger_kind
- biomarker_context Imported condition classification; unverified.
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two single-patient reports of immunoglobulin infusion in patients with low anti-glucan antibody · source_derived_draft · unverified_draft
### bg-adding-antibody-restores-it In two single-patient studies, one in a patient with metastatic colorectal cancer who received BTH1677 combined with the tumour targeting antibody cetuximab and a second in a patient with metastatic neuroendocrine tumour who received BTH1677 combined with the immune checkpoint inhibitor pembrolizumab, the patients had low serum titres of antibodies against beta-glucan and low innate immune effector functionality induced by BTH1677, and addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoural activity with long-term disease control. Condition category: biomarker_context nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: Two patients who lacked the antibody were given antibody, and the drug started working. organism: Human tissue_or_cell_type: Peripheral blood and tumour experimental_model: Two single-patient reports of immunoglobulin infusion in patients with low anti-glucan antibody limitations: Two patients. This is an anecdotal test of a mechanism, not evidence of treatment benefit, and no control condition exists for the tumour outcome. exposure: BTH1677 with cetuximab or with pembrolizumab, plus intravenous immunoglobulin evidence_span: {"source_cache": "artifacts/glucan-research/32132045.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7dea757c889af10839a38a317d704760e7e15798bc15a5da3a1323ec4143cf42", "start_char": 0, "end_char": 1102, "text_sha256": "7dea757c889af10839a38a317d704760e7e15798bc15a5da3a1323ec4143cf42"} [bg-p32132045] Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan. (2020). https://pubmed.ncbi.nlm.nih.gov/32132045/ DOI: 10.21873/anticanres.14090
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.